Best GLP-1 on Cigna Formulary in 2026: 3 Drug Lists Compared

The short answer

The best GLP-1 on Cigna formulary lists depends on which list your plan uses — and that’s not a dodge, it’s the actual finding. Wegovy and Foundayo were on all three Cigna lists. Zepbound was on two of the three — and every document that names it names the pen specifically.

What we opened, and what we couldn’t

Best GLP-1 on Cigna formulary: what each drug list says

Across the three Cigna prescription drug lists we reviewed in July 2026, Wegovy, Wegovy HD, and Foundayo appeared on all three at Tier 2. Zepbound Pen appeared on Standard and Value but was not found on Performance. The separate Express Scripts National Preferred Formulary exclusion file names Zepbound KwikPens and vials as excluded products, with Zepbound pens among the named preferred alternatives.

Legend. Tier 1 = generics · Tier 2 = preferred brands · Tier 3 = non-preferred brands · PA = prior authorization · QL = quantity limit · SP = specialty medication · OC = optional coverage. “Named preferred alternative” means Express Scripts listed the product as an alternative to an excluded one; it does not establish your coverage, tier, or cost. Sources: Cigna Healthcare Standard 3-Tier, Value 3-Tier, and Performance 3-Tier Prescription Drug Lists, all “coverage starting July 1, 2026,” last updated 04/01/2026. Express Scripts 2026 National Preferred Formulary Exclusions, revision 07/01/2026. All read directly on July 18, 2026.

Same insurer, same date, very different lists

Same insurer. Same July 1 effective date. One list has four times as many options as another. That’s why “does Cigna cover it” isn’t a question anyone can answer for you — including us.

The part everyone gets wrong: it’s the presentation, not just the brand

Zepbound comes in three presentations: single-dose pens, the multi-dose KwikPen, and single-dose vials.

The three Cigna lists we opened don’t write “Zepbound.” They write “ZEPBOUND PEN.”

The Express Scripts exclusion file goes further and names the products out loud: under Weight Loss, Zepbound KwikPens and Zepbound Vials are named as excluded, and the named preferred alternatives include Zepbound Pens, Wegovy Pens, Wegovy Tablets, Wegovy HD, Foundayo, and generic liraglutide.

What to say at your appointment:

“Please confirm which Zepbound presentation and dose are medically appropriate for me and covered by my plan. The public documents I’ve looked at distinguish single-dose pens from KwikPens and vials.”

Saxenda versus generic liraglutide

You may see pages saying Saxenda has been dropped from Cigna. That’s incomplete, and acting on the incomplete version costs you a claim.

On the Express Scripts exclusion file, brand-name Saxenda is named as excluded, and generic liraglutide is named as a preferred alternative. On the Cigna Standard and Value lists, Saxenda does appear — at Tier 3, the highest cost-share tier, with prior authorization and optional coverage.

If your plan uses the Express Scripts National Preferred formulary, ask whether the liraglutide alternative applies to your prescription. If your plan uses Standard or Value, Saxenda is there at Tier 3. Either way, ask about liraglutide by ingredient rather than assuming the brand result.

Does every Cigna plan use the Express Scripts formulary?

No. Express Scripts is The Cigna Group’s pharmacy-benefit business, but the National Preferred Formulary is one of several drug list structures Cigna uses. The exclusion file discussed on this page applies only when your plan uses that formulary. Cigna also publishes Standard, Value, Performance, Advantage, Legacy, and multiple National Preferred tier variants, plus state-specific lists.

What this means for you practically: don’t apply the Express Scripts exclusion file to your situation until you know your plan uses that formulary. And don’t apply the Standard list to yourself until you know you’re on Standard.

How to find your list name

1. 1Log in to myCigna (app or myCigna.com). Go to Prescriptions, then Price a Medication.
2. 2Search the exact product, not just the brand. Type “Zepbound Pen,” not “Zepbound.” Search Wegovy and check whether the tablet and the injection return different results. Each presentation is its own product with its own answer.
3. 3Screenshot the result. You want the tier, the coverage codes, the estimated price, and the date. Cigna’s lists say tier moves and removals usually happen twice a year — January 1 and July 1 — so the answer you get today has a shelf life.

Not enrolled yet? Go to Cigna.com/druglist and choose your list from the dropdown.

Can’t find it anywhere? Call the number on your card and read this out loud:

“I need two things. First, the exact name of my prescription drug list. Second, whether my plan includes coverage for FDA-approved weight-management medication, or whether that’s excluded as a benefit category. Those are different questions — please answer both separately.”

Write down the representative’s name, the date, and the reference number. If you end up appealing anything, that record matters.

What PA, QL, SP, and OC mean — and why OC is the one that costs you money

On a Cigna drug list, PA means prior authorization is required, QL means a quantity limit applies, ST means step therapy, SP means specialty-pharmacy rules may apply, and OC means optional coverage. Cigna defines OC as a medication that isn’t usually covered, but that some plans may choose to include.

Here’s the finding.

In our three-list sample, every named weight-management GLP-1 entry carried OC. Zepbound Pen: PA, QL, OC. Wegovy and Wegovy HD: PA, QL, OC. Foundayo: PA, QL, OC. Saxenda, Qsymia, Contrave, phentermine: PA, OC.

Now the diabetes GLP-1s on those same three lists:

None of those twelve entries carried OC. Not one.

That asymmetry is the system in two letters. Diabetes GLP-1s sit on these lists as standard products with a review step. Weight-management GLP-1s sit there flagged as something a plan may or may not have elected. If you’ve been asking “is it on the formulary,” this is the moment to switch questions.

Why is my GLP-1 on the Cigna drug list but still not covered?

A GLP-1 can appear on your Cigna drug list at Tier 2 and still not be covered, because weight-loss medication sits in the standard pharmacy-benefit exclusion list unless your plan includes it. That’s what the OC code signals.

Formulary position is the least important part of your answer.

It tells you which product to name, and naming the wrong presentation costs you weeks. But it is not what decides whether you get the drug.

Here’s the proof, printed in the exclusions section at the back of every Cigna drug list we opened. Cigna lists what plans “generally do not provide coverage for,” and that list includes:

“Medications used for fertility, sexual dysfunction, cosmetic purposes, weight loss, smoking cessation, or athletic enhancement.”

With one qualifier: “except as required by state or federal law, or by the terms of your specific plan.”

Weight-loss medication sits in the standard exclusion list. Your plan has to include it. Cigna’s Standard and Value lists print the warning directly above the weight-management section: “Not all plans cover prescription weight management medications.”

A benefit exclusion is different from a medical-necessity denial. A medical-necessity denial can be reviewed — your prescriber documents why you need it, Cigna looks again. But for a benefit exclusion, the drug “isn’t on your drug list and we can’t approve it through the coverage review process.” The most persuasive letter your prescriber has ever written cannot make a plan pay for something the plan doesn’t include.

Zepbound or Wegovy: which should you actually ask for?

On the Cigna lists that include both, Zepbound Pen and Wegovy appear at the same tier with the same PA, QL, and OC codes. In the phase 3b SURMOUNT-5 head-to-head trial — adults with obesity, or overweight plus a weight-related condition, without type 2 diabetes — tirzepatide produced greater average weight loss than semaglutide at 72 weeks. The trial was open-label and funded by Eli Lilly.

What SURMOUNT-5 found

NEJM 2025;393(1):26-36 · 751 adults · 32 sites in the U.S. and Puerto Rico · 72 weeks. Open-label, Lilly-funded.

The trial was open-label and funded by Eli Lilly. These are averages — individual results vary substantially in both directions.

When Wegovy is the better ask

• •Your plan uses the Performance list. Zepbound wasn't there. Wegovy was. Choosing the drug your plan lists isn't a compromise — it's the fastest legitimate route to treatment.
• •You have established cardiovascular disease. Wegovy has an FDA-approved indication for cardiovascular risk reduction. Zepbound does not. That's a separate pathway — details below.
• •You have MASH with liver fibrosis. Wegovy injection carries the FDA-approved MASH indication. Zepbound does not.
• •You're a parent of a 12-to-17-year-old. Wegovy injection and liraglutide are the two products with pediatric criteria in the reviewed Cigna weight-management policy.
• •You want an oral semaglutide treatment path and the tablet formulation is covered by your plan.

Ask about Zepbound Pen if: you want the option that performed better on average in the head-to-head trial, you’re comfortable with a weekly injection, your list includes it, and your prescriber agrees it fits your history.

Drug-specific detail: Cigna’s Wegovy prior authorization requirements and whether Cigna covers Zepbound.

Is Foundayo the best oral option on Cigna?

Foundayo (orforglipron) is a once-daily weight-loss pill the FDA approved on April 1, 2026. It appeared at Tier 2 on all three Cigna drug lists we reviewed, with prior authorization, quantity limits, and optional-coverage status, and was named as a preferred alternative in the Express Scripts exclusion file. On the Value list it also carries a specialty-medication flag.

It’s a small-molecule pill rather than a peptide — meaning it wasn’t adapted from an injection, it was built as a tablet from the start. Foundayo is taken once daily and may be taken with or without food.

Compare that to Wegovy tablets, which the label directs be taken first thing in the morning on an empty stomach, with no more than four ounces of water, waiting 30 minutes before eating or drinking anything else. For some people’s mornings, that difference decides everything.

On results: at the highest FDA-approved dose, the Foundayo label reports an estimated mean body-weight change of -11.1% at 72 weeks in Trial 1. That is not a head-to-head comparison with Zepbound or Wegovy — different trial, different participants, different design.

The new-drug clause worth knowing about

Foundayo’s appearance on all three lists doesn’t prove every plan finished its review or elected coverage. If Foundayo is the one you want, search it specifically in myCigna before building a plan around it.

Ask about Foundayo if: injections are a non-starter, or the morning fasting window doesn’t fit your life, and it shows as covered on your list.

What does the reviewed Cigna policy require for prior authorization?

Under the Cigna weight-loss GLP-1 coverage policy we reviewed, adults generally need to be 18 or older, have documented behavioral and dietary treatment for at least three months, and have a baseline BMI of 30 or higher — or 27 or higher with at least one listed weight-related condition. The medication is to be used alongside a reduced-calorie diet and behavior change.

The documentation requirement people walk in without

The reviewed policy requires documentation of behavioral modification and dietary treatment for at least three months. The word doing the work is documented — the plan decides whether the evidence submitted is sufficient.

• •Chart notes from previous visits where weight was discussed
• •Records from a prior structured program
• •Prescription receipts or claims records for previous weight-management medication
• •Laboratory or medical test results
• •Any dietitian or counseling records

Ask the prescriber’s office directly: “Which evidence will Cigna accept for this policy?” They deal with this weekly. It’s a normal question.

The BMI math, and the conditions that lower the bar

Qualifying conditions at BMI 27+:

hypertension · type 2 diabetes · dyslipidemia (high cholesterol) · obstructive sleep apnea · cardiovascular disease · knee osteoarthritis · asthma · COPD · fatty liver disease (MASLD) · polycystic ovary syndrome (PCOS) · coronary artery disease

High blood pressure is on it. High cholesterol is on it. Plenty of people who assume they need a BMI of 30 are already through the BMI 27 door.

The baseline definition — this one is worth five minutes

The reviewed policy defines baseline in relation to your weight before any prior GLP-1 or GLP-1/GIP treatment — including compounded products. If you started at BMI 34, lost weight on a compounded product, and you’re at BMI 28 now, the relevant baseline is the pre-treatment one.

Ask your prescriber to document the best-supported pre-treatment weight and date they can source. That record may affect how the plan evaluates both initial and continuation criteria.

One hard stop

What Ro states, and what we verified

How long does approval last, and what do you have to prove to keep it?

In the Cigna weight-management policy we reviewed, initial approval generally runs eight months for the listed semaglutide, tirzepatide, and orforglipron products, and four months for liraglutide. Continuation then runs a year and requires documented weight loss of at least 5% from baseline — 4% for liraglutide, and 10% under the obstructive sleep apnea pathway.

These periods come from the public policy we reviewed. Another Cigna policy version, or your plan document, may use different criteria or periods.

Why eight months is shorter than it sounds

Run the arithmetic against a titration schedule. Zepbound climbs toward its maintenance dose over roughly 20 weeks. Wegovy reaches 2.4 mg in about 16 weeks. Your initial approval window overlaps substantially with the period you spend still climbing.

Two things worth doing well before the window closes:

1. 1Get a dated weight recorded at your prescriber’s office, and ask which weight records your plan accepts for continuation.
2. 2Put the reauthorization on a calendar — yours, not just theirs. If it lapses, you can end up paying full price for a fill in the gap.

What’s the best Cigna GLP-1 for type 2 diabetes?

Mounjaro, Ozempic, Rybelsus, and Trulicity appeared at Tier 2 with prior authorization and quantity limits on all three Cigna drug lists we reviewed — and without the optional-coverage flag that every weight-management GLP-1 carried. If you have type 2 diabetes, you’re looking at a different Cigna policy and different formulary treatment.

We won’t rank these medically. A formulary can tell you what a plan may pay for. It cannot tell you which diabetes medication fits your A1c target, your kidney function, your cardiovascular history, your other medications, or how you tolerate them.

If diabetes is your situation, go to our full breakdown of Cigna’s diabetes GLP-1 coverage or whether Cigna covers Ozempic specifically.

What each one actually costs on Cigna

With Cigna coverage and an approved prior authorization, manufacturer savings offers can bring cost to as little as $25 a month for eligible commercially insured patients. Without coverage, current manufacturer self-pay prices vary by drug, dose, presentation, offer eligibility, and refill timing. All prices verified July 18, 2026.

The question to ask HR, word for word

“Does our plan include the Evernorth benefit option that caps member cost for weight-management GLP-1s at no more than $200 per month?”

The Evernorth cost-cap benefit does something the manufacturer cash programs structurally can’t: the amount you pay applies toward your annual deductible. Cash payments don’t. So $299/month in cash is roughly $3,588 a year that does nothing for your deductible. The same drug at $200/month through the plan is money that’s working twice.

What to do if your Cigna plan excludes weight-loss drugs

The Cigna policy we reviewed contains separate criteria for certain cardiovascular, obstructive sleep apnea, and MASH uses. Meeting an FDA-approved indication or a policy pathway does not override your plan’s terms or guarantee approval, but it can change which coverage request your prescriber submits.

Note the sleep apnea trade-off. Its continuation threshold is 10% weight loss plus the policy’s OSA requirements — double the 5% required under the general adult weight-management pathway.

If none of the pathways fit

Then you’re paying cash, and the news there is better than most people expect. Foundayo at $149/month for the 0.8 mg dose. Wegovy tablets at $149/month for the 1.5 mg dose. Check your maintenance dose price, not just the starting one.

About compounded GLP-1s

Compounded GLP-1s are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they’re marketed. These programs are generally cash-pay, and coverage — if you’re wondering — has to be confirmed with your plan. We’re not saying they’re equivalent to the medications discussed elsewhere on this page, because they aren’t.

Your claim got denied. What now?

Whether a Cigna GLP-1 denial can be corrected depends entirely on the reason. A missing prior authorization, an unlisted presentation, and a quantity limit are different problems from a benefit exclusion. Get the reason in writing before you decide what to do.

Get the reason in writing. These words.

“Please tell me the specific denial reason, the plan provision it’s based on, and whether this is a medical-necessity denial or a benefit exclusion. I’d like that in writing. If it’s a medical-necessity denial, please identify the specific criterion that wasn’t met.”

“Denied” is not information. “Denied because the documented treatment history wasn’t sufficient” is a to-do list.

The Standard and Value lists say it can take up to five business days to hear back after your prescriber sends the requested information. A request for additional information extends that in practice.

If you have Medicare, the answer is different

Medicare Part D does not cover drugs used for weight loss. The Medicare GLP-1 Bridge, a federal program, provides access at a $50 copay for one monthly supply for eligible beneficiaries. GLP-1s prescribed for type 2 diabetes, obstructive sleep apnea, non-cirrhotic MASH, cardiovascular risk reduction, or another Part D–coverable use remain subject to your Part D plan’s formulary and exception process.

Full detail, including eligibility and the current product list, in our Medicare GLP-1 Bridge guide.

How we verified this page

What changes fastest, in order: formulary exclusions and tier placement (Cigna’s lists say changes usually take effect January 1 and July 1), manufacturer self-pay pricing and offer deadlines, and the Medicare Bridge rules.

Frequently asked questions

Sources

1. 1.Cigna Healthcare. Standard 3-Tier Prescription Drug List, coverage starting 07/01/2026; last updated 04/01/2026. cigna.com/druglist
2. 2.Cigna Healthcare. Value 3-Tier Prescription Drug List, coverage starting 07/01/2026; last updated 04/01/2026.
3. 3.Cigna Healthcare. Performance 3-Tier Prescription Drug List, coverage starting 07/01/2026; last updated 04/01/2026.
4. 4.Express Scripts. 2026 National Preferred Formulary Exclusions, revision 07/01/2026.
5. 5.Cigna. Weight Loss — Glucagon-Like Peptide-1 Agonists prior authorization coverage policy.
6. 6.Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. (SURMOUNT-5)
7. 7.U.S. Food and Drug Administration. Foundayo (orforglipron) prescribing information; approved April 1, 2026.
8. 8.U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information.
9. 9.Evernorth Health Services. Evernorth Launches New Benefit Option That Limits Patient Cost to No More Than $200 Per Month, May 21, 2025.
10. 10.LillyDirect. Zepbound and Foundayo self-pay pricing and program terms, accessed July 18, 2026.
11. 11.NovoCare Pharmacy. Wegovy pen and tablet self-pay pricing and savings terms, accessed July 18, 2026.
12. 12.Ro. Pricing, insurance, and GLP-1 coverage checker pages, accessed July 18, 2026.
13. 13.Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge program information.
14. 14.The Cigna Group. Annual report disclosure of the March 2025 sale of Medicare Advantage and standalone Part D businesses to HCSC.
15. 15.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.

This page compares insurance coverage documents and pricing. It is not medical advice and does not determine whether a medication is safe or right for you. Read the FDA prescribing information and talk with a licensed clinician about your medical history, current medications, pregnancy plans, and treatment goals.